Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

SHE:301246 Revenue

Hubei Hongyuan Pharmaceutical Technology had revenue of 638.42M CNY in the quarter ending June 30, 2026, with 42.15% growth. This brings the company's total for the last twelve months to 2.40B, up 36.67% year-over-year. In the year 2025, Hubei Hongyuan Pharmaceutical Technology had annual revenue of 1.94B with 9.53% growth. That makes Hubei Hongyuan Pharmaceutical Technology the 13,253rd largest company in the world by revenue and 2,320th in China.

• Revenue (ttm): 2.40B
• Revenue Growth: +36.67%
• P/S Ratio: 2.64
• Revenue / Employee: 1.06M
• Employees: 2,258
• Market Cap: 6.34B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medicine Manufacturing 1.01B 51.9%
• Chemical Raw Materials and Chemical Products Manufacturing 883.05M 45.5%
• Others 49.53M 2.6%

By Geography

Chart

• China 1.58B 81.7%
• Overseas 355.07M 18.3%

Fiscal year ended Dec 31, 2025 See the full SHE:301246 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.94B	168.75M	9.53%
Dec 31, 2024	1.77B	-284.16M	-13.83%
Dec 31, 2023	2.05B	-8.84M	-0.43%
Jan 1, 2023	2.06B	485.86M	30.79%
Jan 1, 2022	1.58B	274.92M	21.10%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error